Sort   by:  
 Page size 
UnknownPhase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma.
Not available
S-EPMC5946714 | biostudies-literature
UnknownSafety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
Not available
S-EPMC5657013 | biostudies-literature
UnknownPhase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
Not available
S-EPMC4878037 | biostudies-literature
UnknownCombined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
Not available
S-EPMC4226803 | biostudies-literature
UnknownAvelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.
Not available
S-EPMC5493051 | biostudies-literature
UnknownSafety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.
Not available
S-EPMC7587408 | biostudies-literature
Sort   by:  
 Page size